-1.71%
-6.12%
-1.29%
31.11%
210.21%
1010.34%
306.57%
AI Spotlight on ADMA
Company Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin.In addition, it operates source plasma collection facilities.The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc.was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Market Data
| Last Price | 16.1 |
| Change Percentage | -1.71% |
| Open | 16.49 |
| Previous Close | 16.38 |
| Market Cap ( Millions) | 3806 |
| Volume | 2194020 |
| Year High | 23.64 |
| Year Low | 5.02 |
| M A 50 | 18.5 |
| M A 200 | 14.89 |
Financial Ratios
| FCF Yield | 2.08% |
| Dividend Yield | 0.00% |
| ROE | 38.43% |
| Debt / Equity | 48.03% |
| Net Debt / EBIDTA | 25.06% |
| Price To Book | 16.29 |
| Price Earnings Ratio | 55.43 |
| Price To FCF | 48.07 |
| Price To sales | 9.94 |
| EV / EBITDA | 38.9 |
News
- Jan -28 - Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
- Jan -22 - Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
- Jan -20 - There May Still Be Time to Get in on These 3 Trending Biotechs
- Jan -14 - Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
- Jan -10 - ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
- Jan -09 - Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
- Dec -24 - 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
- Dec -20 - ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
- Dec -19 - 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Dec -13 - ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
- Dec -12 - The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
- Dec -11 - ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
- Dec -10 - The Schall Law Firm Urges Shareholder Contributions To An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
- Dec -10 - ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
- Dec -09 - ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm
- Dec -08 - The Schall Law Firm Urges Stockholders To Join An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
- Dec -07 - ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm
- Dec -06 - The Schall Law Firm Urges Public Participation In An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
- Dec -05 - ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
- Dec -04 - The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> ADMA BioManufacturing
Expected Growth : 14 %
What the company do ?
ADMA BioManufacturing is a contract manufacturing organization (CMO) providing fill-finish services for vaccines, proteins, and antibodies from ADMA Biologics, Inc.
Why we expect these perspectives ?
ADMA BioManufacturing's 14% growth is driven by increasing demand for plasma-derived therapies, expansion of commercial partnerships, and investments in manufacturing capacity. Additionally, the growing need for life-saving treatments and rising awareness of rare diseases contribute to the segment's growth.
Segment n°2 -> Plasma Collection Centers
Expected Growth : 13 %
What the company do ?
ADMA Biologics' Plasma Collection Centers collect human plasma used to manufacture life-saving therapies for patients with rare and serious diseases.
Why we expect these perspectives ?
ADMA Biologics' Plasma Collection Centers' 13% growth is driven by increasing demand for life-saving plasma-derived therapies, expansion into new markets, and strategic partnerships. Additionally, advancements in plasma collection technology, growing awareness of rare diseases, and favorable regulatory environments contribute to the segment's growth.
Segment n°3 -> Corporate Segment
Expected Growth : 12 %
What the company do ?
ADMA Biologics' Corporate Segment focuses on developing, manufacturing, and commercializing plasma-derived biologics for the treatment of certain rare immune disorders.
Why we expect these perspectives ?
ADMA Biologics' Corporate Segment growth of 12% is driven by increasing demand for its immunoglobulin products, expansion into new markets, and strategic partnerships. Additionally, investments in research and development, as well as regulatory approvals for new products, contribute to the segment's growth.
Adma Biologics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Nabi-HB | A hepatitis B immune globulin (HBIG) that provides protection against hepatitis B infection |
| Bivigam | An intravenous immune globulin (IVIG) that treats various autoimmune and inflammatory disorders |
| ASCENIV | An intravenous immune globulin (IVIG) that treats primary immunodeficiency diseases |
ADMA Biologics, Inc.'s Porter Forces
Threat Of Substitutes
ADMA Biologics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for immunodeficiency disorders.
Bargaining Power Of Customers
ADMA Biologics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.
Bargaining Power Of Suppliers
ADMA Biologics, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials.
Threat Of New Entrants
ADMA Biologics, Inc. has a high threat of new entrants due to the growing demand for immunodeficiency treatments and the relatively low barriers to entry.
Intensity Of Rivalry
ADMA Biologics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 49.33% |
| Debt Cost | 6.09% |
| Equity Weight | 50.67% |
| Equity Cost | 6.09% |
| WACC | 6.09% |
| Leverage | 97.36% |
ADMA Biologics, Inc. : Quality Control
ADMA Biologics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDYA | IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product … |
| TECH | Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, … |
| INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
| BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Alpine Immune Sciences
A-Score
1-Year Total Return ->
🥈
Bio-Techne
A-Score
1-Year Total Return ->
🥉
ADMA Biologics
A-Score
1-Year Total Return ->
4
Insmed
A-Score
1-Year Total Return ->
5
BridgeBio Pharma
A-Score
1-Year Total Return ->
6
